
## Juliette Sheridan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2405129/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	CRP/Albumin Ratio. Journal of Clinical Gastroenterology, 2018, 52, e48-e52.	2.2	64
2	Nuclear oxidative damage correlates with poor survival in colorectal cancer. British Journal of Cancer, 2009, 100, 381-388.	6.4	44
3	Increased nonâ€melanoma skin cancer risk in young patients with inflammatory bowel disease on immunomodulatory therapy: a retrospective singleâ€centre cohort study. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 978-985.	2.4	16
4	Reduced Serological Response to COVID-19 Vaccines in Patients with IBD is Further Diminished by TNF Inhibitor Therapy; Early Results of the VARIATION study [VAriability in Response in IBD Against SARS-COV-2 ImmunisatiON]. Journal of Crohn's and Colitis, 2022, 16, 1354-1362.	1.3	15
5	Determinants of short- and long-term survival from colorectal cancer in very elderly patients. Journal of Geriatric Oncology, 2014, 5, 376-383.	1.0	14
6	Subcutaneous rather than intravenous ustekinumab induction is associated with comparable circulating drug levels and early clinical response: a pilot study. Alimentary Pharmacology and Therapeutics, 2018, 48, 333-339.	3.7	14
7	Letter: vedolizumab for the management of inflammatory bowel disease in patients after liver transplantation for primary sclerosing cholangitis. Alimentary Pharmacology and Therapeutics, 2017, 45, 376-378.	3.7	12
8	Effects of Radiation on Levels of DNA Damage in Normal Non-adjacent Mucosa from Colorectal Cancer Cases. Journal of Gastrointestinal Cancer, 2013, 44, 41-45.	1.3	10
9	Protocol for a multicentred randomised controlled trial investigating the use of personalised golimumab dosing tailored to inflammatory load in ulcerative colitis: the GOAL-ARC study (GLM dose) Tj ETQq1 1	0,784314 2.7	rgBT /Overl
10	Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis. European Journal of Gastroenterology and Hepatology, 2018, 30, 1019-1026.	1.6	9
11	Letter: Vedolizumab in Pregnancy. Journal of Crohn's and Colitis, 2016, 11, jjw214.	1.3	7
12	Comparison of medium to long-term outcomes of acute severe ulcerative colitis patients receiving accelerated and standard infliximab induction. Frontline Gastroenterology, 2020, 11, 441-447.	1.8	6
13	Editorial: gut selective immunosuppression—is it a double edged sword?. Alimentary Pharmacology and Therapeutics, 2017, 46, 373-373.	3.7	3
14	P261 Grading post-operative recurrence in Crohn's disease: a comparison between MRE and ileocolonoscopy. Journal of Crohn's and Colitis, 2017, 11, S210-S210.	1.3	2
15	The effect of sedation on EGD inspection time. Gastrointestinal Endoscopy, 2021, 94, 875-876.	1.0	1
16	THE USE OF HYOSCINE BUTYLBROMIDE IMPROVES SESSILE SERRATED LESION DETECTION. Endoscopy, 2022, 54, .	1.8	1
17	P578 Evolution of Crohn's disease treatment in clinical practice: a 25 year single centre cohort study. Journal of Crohn's and Colitis, 2017, 11, S375-S375.	1.3	0
18	IMPLEMENTATION OF BOTH BSG 2019 AND ESGE 2020 POLYPECTOMY SURVEILLANCE GUIDELINES SAFELY REDUCES THE BURDEN OF SURVEILLANCE IN A SCREENING COHORT – A VIRTUAL MODEL STUDY. Endoscopy, 2022, 54, .	1.8	0